IONIS FXIRx

Drug Profile

IONIS FXIRx

Alternative Names: BAY-2306001; Factor XI antisense oligonucleotide; FXI ASO; IONIS-FXIRX; ISIS 404071; ISIS-416858; ISIS-FXIRX

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Bayer; Ionis Pharmaceuticals
  • Class Anticoagulants; Antisense oligonucleotides; Antithrombotics
  • Mechanism of Action Factor XI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis; Venous thromboembolism

Most Recent Events

  • 13 Nov 2016 Adverse events and efficacy data from a phase II trial in Thrombosis (Prevention) released by Ionis Pharmaceuticals
  • 01 Nov 2016 Ionis Pharmaceuticals completes a phase II trial in Thrombosis (Prevention) in Canada (SC) (NCT02553889)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top